NIPAL3

Across TCGA pan-cancer cohorts, NIPAL3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated NIPAL3 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NIPAL3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated NIPAL3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

CCRCC, PDAC, and UCEC are the cancer types where NIPAL3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	III,IV	0.460	0.990	.017	4	view →
PDAC	DFS	Tertile	III,IV	0.943	0.214	.038	3	view →
UCEC	DFS	Median	All	1.000	0.801	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

NIPAL3–CCRCC (OS)

Open the CCRCC breakdown →